{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:28:49Z","timestamp":1787156929960,"version":"build-2736575974"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["22-15-00134"],"award-info":[{"award-number":["22-15-00134"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Von Willebrand factor (VWF) is a large multimeric glycoprotein involved in hemostasis. It is essential for platelet adhesion to the subendothelium of the damaged endothelial layer at high shear rates. Such shear rates occur in small-diameter arteries, especially at stenotic sites. Moreover, VWF carries coagulation factor VIII and protects it from proteolysis in the bloodstream. Deficiency or dysfunction of VWF predisposes to bleeding. In contrast, an increase in the concentration of high molecular weight multimers (HMWM) of VWF is closely associated with arterial thrombotic events. Severe aortic stenosis (AS) or hypertrophic obstructive cardiomyopathy (HOCM) can deplete HMWM of VWF and lead to cryptogenic, gastrointestinal, subcutaneous, and mucosal bleeding. Considering that VWF facilitates primary hemostasis and a local inflammatory response at high shear rates, its dysfunction may contribute to the development of coronary artery disease (CAD) and its complications. However, current diagnostic methods do not allow for an in-depth analysis of this contribution. The development of novel diagnostic techniques, primarily microfluidic, is underway. Such methods can provide physiologically relevant assessments of VWF function at high shear rates; however, they have not been introduced into clinical practice. The development and use of agents targeting VWF interaction with the vessel wall and\/or platelets may be reasonable in prevention of CAD and its complications, given the prominent role of VWF in arterial thrombosis.<\/jats:p>","DOI":"10.3389\/fcvm.2022.1038030","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T05:52:16Z","timestamp":1669960336000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Von Willebrand factor in diagnostics and treatment of cardiovascular disease: Recent advances and prospects"],"prefix":"10.3389","volume":"9","author":[{"given":"Sergey","family":"Kozlov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Okhota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Avtaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Melnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Matroze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zufar","family":"Gabbasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","article-title":"Biochemistry and genetics of von Willebrand factor.","volume":"67","author":"Sadler","year":"1998","journal-title":"Annu Rev Biochem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"7899","DOI":"10.1073\/pnas.0608422104","article-title":"Shear-induced unfolding triggers adhesion of von Willebrand factor fibers.","volume":"104","author":"Schneider","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1182\/blood-2014-05-378638","article-title":"von Willebrand factor, Jedi knight of the bloodstream.","volume":"124","author":"Springer","year":"2014","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1172\/JCI119195","article-title":"von Willebrand factor.","volume":"99","author":"Ruggeri","year":"1997","journal-title":"J Clin Invest."},{"key":"B5","doi-asserted-by":"publisher","first-page":"9226","DOI":"10.1073\/pnas.0903679106","article-title":"Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor.","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/MBC.0000000000000065","article-title":"Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.","volume":"25","author":"Stockschlaeder","year":"2014","journal-title":"Blood Coagul Fibrinolysis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood-2012-01-405134","article-title":"Sequence and structure relationships within von Willebrand factor.","volume":"120","author":"Zhou","year":"2012","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood-2018-02-769000","article-title":"Inflammation, von Willebrand factor, and ADAMTS13.","volume":"132","author":"Chen","year":"2018","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"108102","DOI":"10.1103\/PhysRevLett.110.108102","article-title":"Mechanical activation of a multimeric adhesive protein through domain conformational change.","volume":"110","author":"Wijeratne","year":"2013","journal-title":"Phys Rev Lett."},{"key":"B10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.blre.2009.04.001","article-title":"Platelet \u03b1-granules: basic biology and clinical correlates.","volume":"23","author":"Blair","year":"2009","journal-title":"Blood Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends.","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fcvm.2019.00141","article-title":"Shear-dependent platelet aggregation: mechanisms and therapeutic opportunities.","volume":"6","author":"Rana","year":"2019","journal-title":"Front Cardiovasc Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7858","DOI":"10.1038\/ncomms8858","article-title":"Flow-driven assembly of VWF fibres and webs in in vitro microvessels.","volume":"6","author":"Zheng","year":"2015","journal-title":"Nat Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1182\/blood-2011-02-306597","article-title":"Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor.","volume":"118","author":"Crawley","year":"2011","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2141.2004.05009.x","article-title":"Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease: von Willebrand factor regulates ADAMTS-13.","volume":"126","author":"Mannucci","year":"2004","journal-title":"Br J Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/blood-2006-03-010322","article-title":"P-selectin glycoprotein ligand 1 and \u03b22-integrins cooperate in the adhesion of leukocytes to von Willebrand factor.","volume":"108","author":"Pendu","year":"2006","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.29074\/ascls.30.2.65","article-title":"Laboratory diagnosis of von Willebrand disease.","volume":"30","author":"Smith","year":"2017","journal-title":"Clin Lab Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1538-7836.2008.02917.x","article-title":"Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?","volume":"6","author":"Federici","year":"2008","journal-title":"J Thromb Haemost."},{"key":"B19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2450\/2012.0122-11","article-title":"Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange.","volume":"10","author":"Rizzo","year":"2012","journal-title":"Blood Transfus."},{"key":"B20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jacc.2009.09.007","article-title":"Relationship of thrombus healing to underlying plaque morphology in sudden coronary death.","volume":"55","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood-2014-08-528398","article-title":"Diagnostic approach to von Willebrand disease.","volume":"125","author":"Ng","year":"2015","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1477-9560-5-14","article-title":"Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications.","volume":"5","author":"Franchini","year":"2007","journal-title":"Thrombosis J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/ijlh.12345","article-title":"Laboratory diagnosis of von Willebrand disease.","volume":"37","author":"Roberts","year":"2015","journal-title":"Int J Lab Hem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1161\/01.ATV.19.12.3071","article-title":"von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn study.","volume":"19","author":"Jager","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1046\/j.1468-0734.2001.00048.x","article-title":"von Willebrand factor and von Willebrand disease.","volume":"5","author":"Budde","year":"2001","journal-title":"Rev Clin Exp Hematol."},{"key":"B27","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease.","volume":"69","author":"Gill","year":"1987","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1046\/j.1537-2995.2001.41010056.x","article-title":"Influence of ABO blood groups on primary hemostasis.","volume":"41","author":"Moeller","year":"2001","journal-title":"Transfusion."},{"key":"B29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/1076029611422364","article-title":"The influence of the ABO blood type on the distribution of von Willebrand factor in healthy children with no bleeding symptoms.","volume":"18","author":"Akin","year":"2012","journal-title":"Clin Appl Thromb Hemost."},{"key":"B30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1055\/s-2006-947866","article-title":"Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification.","volume":"32","author":"Budde","year":"2006","journal-title":"Semin Thromb Hemost."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05511.x","article-title":"The role of PFA-100R testing in the investigation and management of haemostatic defects in children and adults.","volume":"130","author":"Harrison","year":"2005","journal-title":"Br J Haematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1161\/CIRCRESAHA.113.300156","article-title":"Introduction to aortic stenosis.","volume":"113","author":"Carabello","year":"2013","journal-title":"Circ Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1056\/NEJM195807242590416","article-title":"Gastrointestinal bleeding in aortic stenosis.","volume":"259","author":"Heyde","year":"1958","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0140-6736(92)92434-H","article-title":"Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand\u2019s disease the link?","volume":"340","author":"Warkentin","year":"1992","journal-title":"Lancet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1056\/NEJM200209123471122","article-title":"Gastrointestinal angiodysplasia and aortic stenosis.","volume":"347","author":"Warkentin","year":"2002","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1076029616660759","article-title":"Severe aortic valve stenosis: sustained cure of acquired von Willebrand syndrome after surgical valve replacement.","volume":"23","author":"Frank","year":"2017","journal-title":"Clin Appl Thromb Hemost."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jacc.2010.06.009","article-title":"The development of the von Willebrand syndrome with the use of continuous flow left ventricular assist devices.","volume":"56","author":"Miller","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.jacc.2018.12.045","article-title":"von Willebrand factor and management of heart valve disease.","volume":"73","author":"Van Belle","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/joic.12478","article-title":"Von Willebrand factor revisited.","volume":"31","author":"Yasar","year":"2018","journal-title":"J Interven Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1505643","article-title":"von Willebrand factor multimers during transcatheter aortic-valve replacement.","volume":"375","author":"Van Belle","year":"2016","journal-title":"N Engl J Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1160\/TH09-06-0391","article-title":"Loss of high-molecular-weight von Willebrand factor multimers mainly affects platelet aggregation in patients with aortic stenosis.","volume":"103","author":"Panzer","year":"2010","journal-title":"Thromb Haemost."},{"key":"B42","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1056\/NEJMoa022831","article-title":"Acquired von Willebrand syndrome in aortic stenosis.","volume":"349","author":"Vincentelli","year":"2003","journal-title":"N Engl J Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/jth.12734","article-title":"Shear stress-associated acquired von Willebrand syndrome in patients with mitral regurgitation.","volume":"12","author":"Blackshear","year":"2014","journal-title":"J Thromb Haemost."},{"key":"B44","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/bja\/aeq413","article-title":"Acquired type 2A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery.","volume":"106","author":"Solomon","year":"2011","journal-title":"Br J Anaesth."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood.V106.11.1790.1790","article-title":"Severe aortic and mitral valve regurgitation are associated with von Willebrand factor defect.","volume":"106","author":"Susen","year":"2005","journal-title":"Blood."},{"key":"B46","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1161\/CIRCRESAHA.116.309348","article-title":"Hypertrophic obstructive cardiomyopathy: surgical myectomy and septal ablation.","volume":"121","author":"Nishimura","year":"2017","journal-title":"Circ Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4065\/mcp.2010.0309","article-title":"Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy.","volume":"86","author":"Blackshear","year":"2011","journal-title":"Mayo Clin Proc."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1161\/CIRCULATIONAHA.108.786681","article-title":"Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction.","volume":"118","author":"Le Tourneau","year":"2008","journal-title":"Circulation."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1161\/CIRCULATIONAHA.118.035566","article-title":"Left Ventricular assist devices: synergistic model between technology and medicine.","volume":"138","author":"Han","year":"2018","journal-title":"Circulation."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/MAT.0000000000000157","article-title":"Immediate recovery of acquired von Willebrand syndrome after left ventricular assist device explantation: implications for heart transplantation.","volume":"61","author":"Davis","year":"2015","journal-title":"ASAIO J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis\u2013from experimental insights to the clinic.","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat Rev Drug Discov."},{"key":"B52","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3390\/biomedicines9080915","article-title":"Recognition of oxidized lipids by macrophages and its role in atherosclerosis development.","volume":"9","author":"Mushenkova","year":"2021","journal-title":"Biomedicines."},{"key":"B53","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.3390\/ijms22084080","article-title":"Immunopathology of atherosclerosis and related diseases: focus on molecular biology.","volume":"22","author":"Bezsonov","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"8118","DOI":"10.3390\/ijms21218118","article-title":"Ischemic heart disease pathophysiology paradigms overview: from plaque activation to microvascular dysfunction.","volume":"21","author":"Severino","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/jth.13696","article-title":"von Willebrand factor and inflammation.","volume":"15","author":"Kawecki","year":"2017","journal-title":"J Thromb Haemost."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jth.13142","article-title":"Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register.","volume":"13","author":"Seaman","year":"2015","journal-title":"J Thromb Haemost."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3892\/mmr.2012.1037","article-title":"Correlation of von Willebrand factor gene polymorphism and coronary heart disease.","volume":"6","author":"Xu","year":"2012","journal-title":"Mol Med Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1111\/j.1538-7836.2006.02161.x","article-title":"Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction.","volume":"4","author":"Kaikita","year":"2006","journal-title":"J Thromb Haemost."},{"key":"B59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/2048872614534388","article-title":"Plasma levels of active von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study.","volume":"4","author":"Rutten","year":"2015","journal-title":"Eur Heart J Acute Cardiovasc Care."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1182\/blood-2006-07-038166","article-title":"ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.","volume":"109","author":"Chion","year":"2007","journal-title":"Blood."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3892\/etm.2015.2721","article-title":"Plasma von Willebrand factor level is transiently elevated in a rat model of acute myocardial infarction.","volume":"10","author":"Li","year":"2015","journal-title":"Exp Ther Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1053\/euhj.2001.3237","article-title":"von Willebrand factor and coronary heart disease. Prospective study and meta-analysis.","volume":"23","author":"Whincup","year":"2002","journal-title":"Eur Heart J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1161\/01.CIR.0000120705.55512.EC","article-title":"Endothelial cell markers and the risk of coronary heart disease: the prospective epidemiological study of myocardial infarction (PRIME) study.","volume":"109","author":"Morange","year":"2004","journal-title":"Circulation."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e55175","DOI":"10.1371\/journal.pone.0055175","article-title":"Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses.","volume":"8","author":"Willeit","year":"2013","journal-title":"PLoS One."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1161\/01.CIR.96.4.1102","article-title":"Prospective study of hemostatic factors and incidence of coronary heart disease: the atherosclerosis risk in communities (ARIC) study.","volume":"96","author":"Folsom","year":"1997","journal-title":"Circulation."},{"key":"B66","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.1999.01317.x","article-title":"Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly heart study.","volume":"105","author":"Rumley","year":"1999","journal-title":"Br J Haematol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1161\/01.CIR.98.21.2241","article-title":"High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.","volume":"98","author":"Th\u00f6gersen","year":"1998","journal-title":"Circulation."},{"key":"B68","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1161\/01.ATV.17.11.3321","article-title":"Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh artery study.","volume":"17","author":"Smith","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1111\/j.1538-7836.2006.01949.x","article-title":"von Willebrand factor, endothelial dysfunction, and cardiovascular disease.","volume":"4","author":"Vischer","year":"2006","journal-title":"J Thromb Haemost."},{"key":"B70","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJM199503093321003","article-title":"Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris.","volume":"332","author":"Thompson","year":"1995","journal-title":"N Engl J Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/eurheartj\/ehi104","article-title":"Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome.","volume":"26","author":"Ray","year":"2005","journal-title":"Eur Heart J."},{"key":"B72","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/hrt.66.5.351","article-title":"von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.","volume":"66","author":"Jansson","year":"1991","journal-title":"Heart."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"Reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.","volume":"350","author":"Danesh","year":"2004","journal-title":"N Engl J Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12959-017-0151-3","article-title":"vWF\/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease.","volume":"15","author":"Warlo","year":"2017","journal-title":"Thrombosis J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/euhj.1998.1194","article-title":"Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease; Edinburgh artery study.","volume":"20","author":"Price","year":"1999","journal-title":"Eur Heart J."},{"key":"B76","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0140-6736(92)91401-S","article-title":"Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus.","volume":"340","author":"Stehouwer","year":"1992","journal-title":"Lancet."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/S0002-9149(97)00749-2","article-title":"Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy.","volume":"80","author":"Lip","year":"1997","journal-title":"Am J Cardiol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.amjhyper.2004.09.003","article-title":"High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage\/dysfunction.","volume":"18","author":"Lee","year":"2005","journal-title":"Am J Hypertens."},{"key":"B79","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1172\/JCI9516","article-title":"Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.","volume":"106","author":"Kaufmann","year":"2000","journal-title":"J Clin Invest."},{"key":"B80","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/01.CIR.98.4.294","article-title":"Early Increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin.","volume":"98","author":"Montalescot","year":"1998","journal-title":"Circulation."},{"key":"B81","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/01.ATV.0000051384.43104.FC","article-title":"Endothelial dysfunction: a marker of atherosclerotic risk.","volume":"23","author":"Bonetti","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1093\/rheumatology\/34.9.814","article-title":"Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis.","volume":"34","author":"Blann","year":"1995","journal-title":"Rheumatology."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e000162","DOI":"10.1136\/lupus-2016-000162","article-title":"Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation.","volume":"3","author":"Nossent","year":"2016","journal-title":"Lupus Sci Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/00019501-200512000-00009","article-title":"Time course of release of inflammatory markers after coronary stenting: comparison between bare metal stent and sirolimus-eluting stent.","volume":"16","author":"Kefer","year":"2005","journal-title":"Coron Artery Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/0049-3848(89)90317-4","article-title":"von Willebrand factor is an acute phase reactant in man.","volume":"53","author":"Pottinger","year":"1989","journal-title":"Thromb Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e23939","DOI":"10.1002\/jcla.23939","article-title":"Kinetics of platelet adhesion to a fibrinogen-coated surface in whole blood under flow conditions.","volume":"35","author":"Gabbasov","year":"2021","journal-title":"J Clin Lab Anal."},{"key":"B87","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/09537104.2017.1306042","article-title":"Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders.","volume":"28","author":"Schoeman","year":"2017","journal-title":"Platelets."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1039\/C7LC00498B","article-title":"Application of a strain rate gradient microfluidic device to von Willebrand\u2019s disease screening.","volume":"17","author":"Brazilek","year":"2017","journal-title":"Lab Chip."},{"key":"B89","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1182\/bloodadvances.2020002117","article-title":"Platelet \u03b1-granules are required for occlusive high-shear-rate thrombosis.","volume":"4","author":"Kim","year":"2020","journal-title":"Blood Adv."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/j.1538-7836.2011.04464.x","article-title":"A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions: thrombus formation and antithrombotic interventions under flow.","volume":"9","author":"Hosokawa","year":"2011","journal-title":"J Thromb Haemost."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1172\/JCI115198","article-title":"Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.","volume":"87","author":"Sobel","year":"1991","journal-title":"J Clin Invest."},{"key":"B92","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0014-2999(02)01590-X","article-title":"Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis.","volume":"443","author":"Kageyama","year":"2002","journal-title":"Eur J Pharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0049-3848(00)00430-8","article-title":"Anti-human vWF monoclonal antibody, AJvW-2 fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs.","volume":"101","author":"Kageyama","year":"2001","journal-title":"Thromb Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/01.ATV.19.4.877","article-title":"AJvW-2, an anti-vWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes.","volume":"19","author":"Eto","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1161\/CIRCULATIONAHA.107.724864","article-title":"First-in-human evaluation of anti\u2013von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.","volume":"116","author":"Gilbert","year":"2007","journal-title":"Circulation."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1161\/STROKEAHA.111.616649","article-title":"The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial.","volume":"42","author":"Markus","year":"2011","journal-title":"Stroke."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.3324\/haematol.2019.235549","article-title":"Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab.","volume":"105","author":"Sakai","year":"2019","journal-title":"Haematologica."},{"key":"B98","doi-asserted-by":"publisher","first-page":"11180","DOI":"10.1038\/s41598-020-68125-9","article-title":"The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin.","volume":"10","author":"Kovacevic","year":"2020","journal-title":"Sci Rep."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1055\/s-0040-1713888","article-title":"von Willebrand factor predicts mortality in ACS patients treated with potent P2Y12 antagonists and is inhibited by aptamer BT200 ex vivo.","volume":"120","author":"Kovacevic","year":"2020","journal-title":"Thromb Haemost."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ymthe.2019.03.016","article-title":"Preclinical development of a vWF aptamer to limit thrombosis and engender arterial recanalization of occluded vessels.","volume":"27","author":"Nimjee","year":"2019","journal-title":"Mol Ther."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1111\/bph.13178","article-title":"A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury: anfibatide protects mice from ischaemic stroke and reperfusion injury.","volume":"172","author":"Li","year":"2015","journal-title":"Br J Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"111698","DOI":"10.1016\/j.biopha.2021.111698","article-title":"Blockade of platelet glycoprotein receptor Ib ameliorates blood-brain barrier disruption following ischemic stroke via Epac pathway.","volume":"140","author":"Chu","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B103","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1038\/s41598-021-91165-8","article-title":"In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIb\u03b1.","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep."},{"key":"B104","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/phar.2620","article-title":"Safety and efficacy of a platelet glycoprotein Ib inhibitor for patients with non-ST segment elevation myocardial infarction: a phase Ib\/IIa study.","volume":"41","author":"Zheng","year":"2021","journal-title":"Pharmacotherapy."},{"key":"B105","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura.","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1160\/TH10-12-0804","article-title":"The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention.","volume":"106","author":"van Loon","year":"2011","journal-title":"Thromb Haemost."},{"key":"B107","first-page":"A15084","article-title":"Abstract 15084: safety and efficacy of anti-von Willebrand factor nanobody\u00ae ALX-0081 in stable angina patients undergoing percutaneous coronary intervention.","volume":"122","author":"Bartunek","year":"2010","journal-title":"Circulation."},{"key":"B108","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12265-012-9435-y","article-title":"Novel antiplatelet agents: ALX-0081, a nanobody directed towards von Willebrand factor.","volume":"6","author":"Bartunek","year":"2013","journal-title":"J Cardiovasc Trans Res."},{"key":"B109","doi-asserted-by":"publisher","first-page":"e007004","DOI":"10.1161\/JAHA.117.007004","article-title":"Recombinant human ADAMTS13 treatment improves myocardial remodeling and functionality after pressure overload injury in mice.","volume":"7","author":"Witsch","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"B110","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1182\/blood-2012-06-439935","article-title":"Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia\/reperfusion injury in mice.","volume":"120","author":"De Meyer","year":"2012","journal-title":"Blood."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e66960","DOI":"10.1371\/journal.pone.0066960","article-title":"The GPVI-Fc fusion protein revacept improves cerebral infarct volume and functional outcome in stroke.","volume":"8","author":"Goebel","year":"2013","journal-title":"PLoS One."},{"key":"B112","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","article-title":"Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein VI, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled ISAR-PLASTER phase 2 trial.","volume":"6","author":"Mayer","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1055\/s-0040-1721078","article-title":"Revacept, an inhibitor of platelet adhesion in symptomatic carotid artery stenosis: design and rationale of a randomized phase II clinical trial.","volume":"4","author":"Gr\u00f6schel","year":"2020","journal-title":"TH Open."},{"key":"B114","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2021011776","article-title":"Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.","volume":"139","author":"de Maat","year":"2022","journal-title":"Blood."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1038030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T05:52:21Z","timestamp":1669960341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1038030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":114,"alternative-id":["10.3389\/fcvm.2022.1038030"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1038030","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"article-number":"1038030"}}